ProCE Banner Activity

A Cancer Conversation: Optimizing the Care of Patients With CLL Through a Deeper Understanding of BTK Inhibitor Resistance

Podcast Episodes

Listen to expert perspectives on selecting optimal therapy for patients with CLL, with a focus on how BTK inhibitor resistance mutations are assessed and how they affect therapy choice. 

Released: October 01, 2024

Expiration: September 30, 2025

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by an educational grant from AstraZeneca

AstraZeneca

Disclosure

Primary Author

Matthew S Davids, MD, MMSc

Associate Professor of Medicine
Harvard Medical School
Leader, Lymphoma Program
Dana-Farber/Harvard Cancer Center
Director of Clinical Research
Division of Lymphoma
Dana-Farber Cancer Institute
Boston, Massachusetts

Matthew S. Davids, MD, MMSc: consultant/advisor/speaker: AbbVie, Ascentage Pharma, AstraZeneca, BeiGene, Bristol Myers Squibb, Genentech, Genmab, Janssen, Lilly, MEI Pharma, Merck, Nuvalent, SecuraBio, Takeda, TG Therapeutics; researcher: Ascentage Pharma, MEI Pharma, Novartis.

Lindsey Roeker, MD

Assistant Attending
CLL Program Director
Department of Medicine
Memorial Sloan Kettering Cancer Center
New York, New York

Lindsey Roeker, MD: consultant/advisor/speaker: AbbVie, Ascentage, AstraZeneca, BeiGene, Curio, DAVA, Janssen, Loxo Oncology, Pharmacyclics, Pfizer; data and safety monitoring committee: Ascentage; owner (minority ownership interest): Abbott; researcher (paid to institution): AbbVie, Adaptive Biotechnologies, Aptose Biosciences, AstraZeneca, Dren Bio, Genentech, Loxo Oncology, Pfizer, Qilu Puget Sound Biotherapeutics.